Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 24 for “"Castration-Resistant Prostate Cancer (CRPC)"”.
-
Germline HOXB13 G84E Mutation Inhibits MEIS1-HOXB13 Driven Tumor Suppression in Prostate Cancer
Prostate cancer (PrCa) continues to pose a burden to adult men in the United States, having the highest incidence and second highest mortality rates. A prostate cancer diagnosis in an immediate family member increases risk 2-3 fold. Standard of care treatment of PrCa targets the Androgen Receptor …
-
Tmprss2-Erg Regulation Of Androgen Biosynthetic Enzyme Expression, Dht Synthesis, And Androgen Receptor Activation In Prostate Cancer
<p>Intratumoral androgen synthesis in prostate cancer (PCa) contributes to the development of castration-resistant prostate cancer (CRPC). Several enzymes responsible for androgen biosynthesis have been shown to be overexpressed in CRPC, thus, contributing to CRPC in a castrated environment. …
-
Androgen Receptor and Prostate Cancer Cell Heterogeneity
… receptor (AR) plays an important role in prostate cancer (PCa) development and has been the main therapeutic target in advanced PCa. AR expression is heterogeneous in both primary PCa and castration resistant prostate cancer (CRPC). However, the functional significance of AR heterogeneity …
-
The development of a novel therapeutic strategy for the treatment of prostate cancer by targeting metabolic signalling
Prostate cancer is one of the most prevalent cancers worldwide. The early stages of prostate cancer (PCa) are highly dependent on the androgen receptor (AR) pathway and hence therapies target this signalling axis. This approach is successful initially but invariably fails and the tumours progress …
-
Grk3 Connects Angiogenesis and Neuroendocrine Differentiation In Prostate Cancer By Activating Hdac2 That Epigenetically Represses Tsp1 and Rest
<p>Prostate cancer (PCa) is the second most frequent cancer and the second leading cause of mortality in men in the United States. Neuroendocrine prostate cancer (NEPC) is the aggressive subset of castration-resistant prostate cancer (CRPC), found in ~20% lethal CRPC. The mechanisms underlying the …
-
Quantitative analyses to study tumor clones dynamics and tumor heterogeneity
Prostate cancer is a highly heterogeneous disease and its manifestations can vary from indolent localized tumor to widespread metastases. This heterogeneity is also observed at the molecular level both inter- and intra-patient. Intra-patient heterogeneity in the clinical setting of men with …
-
Intratumoral Sting Activation Sensitizes Poorly Immunogenic Cancers to Checkpoint Blockade Immunotherapy
… rare and are not observed in all tumor types. Castration resistant prostate cancer (CRPC) and pancreatic adenocarcinoma (PDAC) are two common lethal cancers that remain refractory to checkpoint blockade, requiring development of new therapeutic approaches to promote responsivity in patients …
-
Detection of AR gene rearrangements and regulation of AR variant-driven prostate cancer models
Prostate cancer is one of the leading causes of death for men in the United States. The androgen receptor (AR) plays a central role in normal prostate development and homeostasis, but prostate cancer cells are also dependent on AR signaling for growth and survival. AR is the target for most …
-
Finding the Best Gene Candidate(s) as a Potential Therapeutic Target for N-MYC Overexpressing Neuroendocrine Prostate Cancer (NEPC)
Neuroendocrine prostate cancer (NEPC) is the most aggressive form of prostate tumorigenesis. Recent studies have shown that one of the key genes that regulate the development of NEPC cells is the N-MYC oncogene, along with the loss of tumor suppressors such as TP53 and RB1 (Lee et al., 2016). …
-
Investigation of the Anti-Proliferative and Pro-Apoptotic Effects of Rosemary (Rosmarinus officinalis) Extract on Androgen Independent Prostate Cancer Cells
… is established as the third most prevalent cancer type in the worldwide population and accounts for 21% of new cancer cases in Canadian men. Prostate cancer can be categorized as androgen dependent or androgen independent, indicative of the tumor’s ability to respond to testosterone …
-
TMEFF2 is an epigenetic modulator that promotes androgen independent growth in castration-resistant prostate cancer cells
… the disease remains the second leading cause of cancer related deaths in men. Most patients initially respond to androgen deprivation treatment; however, a significant percentage of patients relapse with currently untreatable castration resistant prostate cancer (CRPC), during which the PCa cells …
-
Engineering Lipid Nanoparticles for sIRNA Delivery to Silence Identified Targest in Cancer Cells
… provides a comprehensive overview of the breast cancer treatment landscape, discussing established therapies like hormone therapy and HER family receptor inhibitors, as well as emerging and experimental strategies such as immune checkpoint inhibitors and kinase inhibitors. This chapter …
-
Identification and Targeting of Downstream Ar-Camkk2-Mediated Mechanisms For The Treatment of Advanced Prostate Cancer
… androgen receptor (AR) is the primary driver of prostate cancer and, therefore, AR-regulated signaling events are essential for the development and progression of the disease. Despite their initial effectiveness, drugs targeting AR eventually fail as sustained inhibition of receptor activity …
-
Phage Display Library Screening For Psa-/Lo Prostate Cancer Cell-Binding Peptides
<p>Prostate cancer (PCa) is one of the leading malignancies affecting men worldwide. Our lab focuses on understanding the molecular mechanisms underlying prostate carcinogenesis and developing therapeutics that target the cells responsible for driving PCa and mediating therapy resistance. My master …
-
Investigating the expression and function of aldehyde dehydrogenases in prostate cancer. Probing the expression and function of ALDHs using chemical probes, drugs and siRNA
Castration-resistant prostate cancer (CRPC) remains an aggressive incurable disease in men mainly due to treatment resistance. Current treatments do not effectively eradicate cancer stem cells (CSCs), which play a pivotal role in tumour maintenance, progression and drug resistance. Aldehyde …
-
Investigating the expression and function of aldehyde dehydrogenases in prostate cancer. Probing the expression and function of ALDHs using chemical probes, drugs and siRNA
Castration-resistant prostate cancer (CRPC) remains an aggressive incurable disease in men mainly due to treatment resistance. Current treatments do not effectively eradicate cancer stem cells (CSCs), which play a pivotal role in tumour maintenance, progression and drug resistance. Aldehyde …
-
Estrogen receptor beta modulates prostate carcinogenesis
Prostate cancer (PC) is characterised by dependence upon androgen receptor (AR) as its driving oncogene. When organ-confined, radical treatment can be curative, however there is no cure for advanced, castration-resistant prostate cancer (CRPC). There is therefore a need to better understand the …
-
Investigation of the role of Col4a1 and Itga11 in enzalutamide resistance of prostate cancer cells
Prostate carcinoma is the most commonly diagnosed non-cutaneous cancer in males in the Western World. Androgen Deprivation Therapy (ADT) is initially effective in patients with localized prostate cancer (PCa), but eventually, cancer cells develop resistance to therapy and progress into …
-
Therapeutic Effects and Targeted Delivery of Eupenifeldin in Castration-Resistant Prostate Cancer
Castration-resistant prostate cancer (CRPC) poses a major therapeutic challenge, as it often fails to respond to standard treatments such as taxane-based chemotherapies, androgen receptor pathway inhibitors, and radioligand-based approaches1–4. Despite these treatments, CRPC remains incurable, and …
-
IDENTIFICATION OF NCAM1 AS A NOVEL PROGNOSTIC PROSTATE CANCER STEM CELL BIOMARKER
Serum prostate-specific antigen and Gleason grade are parameters routinely used for risk stratification in prostate cancer (PCa), but they present some limitations in the prediction of disease progression and in their use to guide clinical decision making. Prostate cancer stem cells (PCSCs) are …
Page 1 of 2